Stock Take Ellie Donnelly: Cathal Friel’s Hvivo gives investors reason for cheerThe veteran entrepreneur is continuing his success of listing in London having ‘totally given up on’ the Irish Stock Exchange
Companies Increased demand boosts revenues at Hvivo as it eyes acquisitionsEarnings rose 44 per cent, ahead of analyst expectations
Companies Cathal Friel’s Hvivo plans cash return for investors as sales are forecast to hit £100m by 2028The Irish pharmaceutical services company confirmed it will pay a full year dividend to shareholders after already returning £3m last year
Companies Hvivo signs €7.3m contract to test common cold treatment Study will evaluate the effect of the antiviral candidate on viral load, safety and tolerability against HRV infection in healthy volunteers
Pharma Poolbeg Pharma could reach €1bn valuation, says chief executive Dublin-headquartered biopharma company is targeting the growing infectious disease market
Pharma Hvivo raises full year sales and earnings guidance after ‘excellent’ start to 2023The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent
Companies Hvivo to move to larger “state-of-the-art” facility in LondonThe Dublin-headquartered pharmaceutical services company said the expanded facility would allow it to capitalise on its growing order book
Companies Hvivo reports double-digit sales and profit growth for the first half of the yearThe pharmaceutical services company founded by businessman Cathal Friel said it is on track to deliver full year earnings of €9 to €12 million
Business Amryt Pharma’s Friel plans yet another IPO later this yearDonegal businessman has already brought three companies public as well as Amryt: Fastnet Oil & Gas, Hvivo and Poolbeg Pharma
Companies Hvivo hails ‘transformative’ year after trebling earningsContracted order-book increased by 65 per cent to £76 million
Health Irish-founded hVIVO lands €7.5m contract to test vaccinesThe trials are aimed at eliminating respiratory diseases which kill thousands of people each year
Companies Hvivo to make return to shareholders from strong 2022 resultsPharmaceutical services company expects full-year revenues of £50.6 million for 2022, a 30 per cent increase year-on-year